Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 16, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details a change in the holdings of the GlaxoSmithKline US Retirement Savings Plan ("the Plan") resulting from a fund movement on February 15, 2007:
- Previous Holdings: 16,417,793 Ordinary Share ADRs
- New Holdings: 16,392,345 Ordinary Share ADRs
- Net Change: Decrease of 25,448 ADRs
- Average Price: $56.38
Two directors, Dr. J P Garnier and Dr. M M Slaoui, are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses compliance with Disclosure Rule 3.1.4R(1)(b) regarding the reported transaction.
Key Facts for Investor Verification
- Verify the impact of the 25,448 ADR reduction on the total beneficial ownership of the named directors.
- Confirm the average transaction price of $56.38 against market data for February 15, 2007.
- Note that the transaction was executed by the Plan Administrators, not directly by the directors.